On July 1, 2022 FibroGen, Inc. (NASDAQ: FGEN) reported that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 taking place the week of July 11, 2022 (Press release, FibroGen, JUL 1, 2022, View Source [SID1234616433]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the event will be available Monday, July 11 at 9:00am ET on the "Events & Presentations" section of the FibroGen Investors webpage at www.fibrogen.com. The replay will be available for approximately 30 days.

On July 1, 2022 Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, reported that it has entered into a securities purchase agreement with institutional investors ("Investors") in the form of senior secured convertible notes (the "Notes") and warrants exercisable for Ensysce common stock (the "Warrants") in a private placement for an aggregate investment of $8 million (Press release, Ensysce Biosciences, JUL 1, 2022, View Source [SID1234616432]). The initial closing on June 30th provided $4 million on July 1st, prior to fees and offering expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Lynn Kirkpatrick, CEO of Ensysce commented, "The financing is an excellent step allowing us to advance the clinical development of our highly unique TAAP and MPAR technologies. The funding will support the completion of a number of upcoming studies and milestones, including our two Human Abuse Potential studies that we believe will support abuse deterrent labeling of PF614, and the first overdose protection human trial with PF614-MPAR. We are very pleased that we were able to secure this additional funding to continue our progress and support our mission to deliver superior pain relief options while also providing abuse and overdose protection for opioid products."

The Notes, with total gross proceeds expected to be $8 million before fees and expenses, are convertible into shares of Ensysce common stock at a conversion price of $0.545, a 10% premium to the base price set at the time of the initial closing. The Notes have a maturity date of 18 months from the applicable closing date, were issued with an original discount of 6% and will bear interest from date of issuance at 6% per annum. Monthly principal payments in cash or common stock will begin approximately 90 days after each respective closing. The Warrants issued at the initial closing have the right to purchase up to 4,667,890 shares of common stock at an exercise price of $0.7085, a 30% premium to the conversion price, and are exercisable for five years following the date of issuance. An initial $4 million of funding was secured upon the initial closing with a second closing of $4 million under similar terms expected to occur upon satisfaction of certain conditions.

Lake Street Capital Markets LLC is acting as the sole placement agent in connection with the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. This news release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended.

On July 1, 2022, Century Therapeutics, Inc. (the "Company"), reported that entered into a Sales Agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen"), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the "Shares"), having an aggregate offering price of up to $150 million through Cowen as sales agent (Filing, 8-K, Century Therapeutics, JUL 1, 2022, View Source [SID1234616431]). The issuance and sale, if any, of Shares by the Company under the Sales Agreement is subject to the effectiveness of the Company’s registration statement on Form S-3 (the "Registration Statement"), filed with the Securities and Exchange Commission on July 1, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the Sales Agreement, Cowen may sell Shares by any method permitted by law deemed to be an "at-the-market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Global Select Market or any other existing trading market for the Shares. Cowen will use commercially reasonable efforts to sell the Shares from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Cowen a commission of 3.0% of the gross proceeds from the sales of Shares sold through Cowen under the Sales Agreement and has provided Cowen with customary indemnification and contribution rights. The Company will also reimburse Cowen for certain expenses incurred in connection with the Sales Agreement.

The Company is not obligated to make any sales of Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms.

The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is attached as Exhibit 1.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any Shares, nor shall there be any sale of such Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

On July 1, 2022 Taiho Pharmaceutical Co., Ltd. reported the launch of the second Taiho Smile Support, the company’s unique social contribution program (Press release, Taiho, JUL 1, 2022, View Source [SID1234616429]). Under the program, Taiho Pharmaceutical will solicit project proposals on the theme of "Challenging Issues in the Field of Oncology" via its website from July 1 to September 30, 2022 .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Taiho Smile Support is a social contribution program that supports organizations and individuals seeking to work on solving various social issues in the field of oncology that cannot be solved by drugs alone, using crowdfunding. If a selected organization or individual starts crowdfunding and is able to raise 50% of the amount needed to carry out the project, they will also receive a matching funds from Taiho Pharmaceutical equal to 50% of the amount needed to carry out the project.

In the first Taiho Smile Support, Taiho Pharmaceutical donated a total of 4.17 million yen in matching funds to three projects. Those three projects are currently underway.

On June 5, 2022 Jacobio Pharma (1167.HK) announced the phase I clinical data of KRAS G12C inhibitor JAB-21822 at the 2022 annual meeting of American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) (Press release, Jacobio Pharmaceuticals, JUN , 2022, View Source [SID1234615590]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of April 1, 2022, the Phase I clinical data of non-small cell lung cancer patients with KRAS G12C mutation shows that the overall response rate (ORR) is 56.3% (18/32) and the disease control rate (DCR) is 90.6% (29/32). In 400mg QD and 800mg QD cohorts, the ORR is 66.7% (8/12) and the DCR is 100% (12/12).

JAB-21822 was well tolerated with no dose limited toxicity (DLTs) in the dose escalation phase. The study of the clinical trial is still ongoing and remains open to enrollment.

The e-poster presentation materials has been available at 8:00 a.m. (Central Time) on June 5, 2022 at www.asco.org.

Conference Call Information
Jacobio will host JAB-21822 data discussion and business update call on June 6 9:00am-10:00am (HKT).
Registration link: View Source

About JAB-21822
JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors, including monotherapy for STK11 co-mutated non-small cell lung cancer in a front-line setting; combination therapy with SHP2 inhibitor, PD-1 monoclonal antibody and Cetuximab.